Cargando…

Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK

INTRODUCTION: Patients with type 2 diabetes mellitus (T2DM) who fail to meet glycaemic control are at increased risk of diabetes complications. For patients who cannot maintain glycaemic control with oral medication, one recommended option is to add an injectable glucagon-like peptide-1 receptor ago...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boye, Kristina S., Stein, Dara, Matza, Louis S., Jordan, Jessica, Yu, Ren, Norrbacka, Kirsi, Hassan, Syed Wasi, García-Pérez, Luis-Emilio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544605/ https://www.ncbi.nlm.nih.gov/pubmed/31115873 http://dx.doi.org/10.1007/s40268-019-0273-0

Ejemplares similares

Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes
por: Matza, Louis S., et al.
Publicado: (2021)

GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data
por: Divino, Victoria, et al.
Publicado: (2019)

GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries
por: Divino, Victoria, et al.
Publicado: (2017)

Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes
por: Matza, Louis S, et al.
Publicado: (2018)

Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis
por: Zimner Rapuch, Sarah, et al.
Publicado: (2021)

Evaluating the Impact of Therapy on Quality of Life in Type 2 Diabetes: A Literature Review of Utilities Associated with Treatment-Related Attributes
por: Valentine, William, et al.
Publicado: (2022)

Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK
por: Gelhorn, Heather L, et al.
Publicado: (2015)

Development of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ)
por: Matza, Louis S., et al.
Publicado: (2018)

Patient Perceptions of and Preferences Between Characteristics of Injectable Diabetes Treatments
por: Boye, Kristina S., et al.
Publicado: (2021)

Validation of two generic patient-reported outcome measures in patients with type 2 diabetes
por: Matza, Louis S, et al.
Publicado: (2007)

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes
por: Boye, Kristina S., et al.
Publicado: (2020)

Development of a Patient-Reported Outcome (PRO) Measure to Assess Emotional Impact of Treatment for Type 2 Diabetes
por: Boye, Kristina S., et al.
Publicado: (2023)

Evaluating health-related quality of life in type 1 diabetes: a systematic literature review of utilities for adults with type 1 diabetes
por: Smith-Palmer, Jayne, et al.
Publicado: (2016)

Impact of caregiver and parenting status on time trade-off and standard gamble utility scores for health state descriptions
por: Matza, Louis S, et al.
Publicado: (2014)

Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK
por: Hall, G C, et al.
Publicado: (2013)

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics
por: García-Pérez, Luis-Emilio, et al.
Publicado: (2021)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Validity and analysis of the Diabetes Injection Device Preference Questionnaire (DID-PQ)
por: Boye, Kristina S., et al.
Publicado: (2020)

Development of a patient-reported outcome (PRO) measure to assess patient perceptions of simplicity and complexity of treatment for type 2 diabetes
por: Stewart, Katie D., et al.
Publicado: (2023)

Patient preferences for glucagon-like peptide 1 receptor–agonist treatment attributes
por: Thieu, Vivian T, et al.
Publicado: (2019)

The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)

GLP-1 Receptor Agonists and Kidney Protection
por: Greco, Eulalia Valentina, et al.
Publicado: (2019)

Clinical Trial Highlights – GLP-1 agonists
por: McFarthing, Kevin, et al.
Publicado: (2020)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
por: Miñambres, Inka, et al.
Publicado: (2017)

The longitudinal link between visual acuity and health-related quality of life in patients with diabetic retinopathy
por: Matza, Louis S, et al.
Publicado: (2008)

Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist
por: Wang, Qinghua, et al.
Publicado: (2010)

The time horizon matters: results of an exploratory study varying the timeframe in time trade-off and standard gamble utility elicitation
por: Matza, Louis S., et al.
Publicado: (2015)

Basal Insulin Use With GLP-1 Receptor Agonists
por: Anderson, Sarah L., et al.
Publicado: (2016)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
por: Zhao, Xin, et al.
Publicado: (2021)

Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes
por: Matza, Louis S., et al.
Publicado: (2017)

Exit Interviews Examining the Patient Experience in Clinical Trials of Tirzepatide for Treatment of Type 2 Diabetes
por: Matza, Louis S., et al.
Publicado: (2022)

GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
por: Górriz, José Luis, et al.
Publicado: (2020)

Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain
por: Norrbacka, Kirsi, et al.
Publicado: (2021)

Brain GLP‐1 and the regulation of food intake: GLP‐1 action in the brain and its implications for GLP‐1 receptor agonists in obesity treatment
por: Trapp, Stefan, et al.
Publicado: (2021)

Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study
por: Federici, Marco Orsini, et al.
Publicado: (2018)

Psychometric evaluation of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ)
por: Matza, Louis S., et al.
Publicado: (2018)

Patient-Reported Outcomes and Impact of Type 2 Diabetes: A Cross-Sectional Study in the Kingdom of Saudi Arabia
por: Gelhorn, Heather L, et al.
Publicado: (2020)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages
por: Whitley, Heather P., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g1ttqnvd3si2roi3tjq3k2jklf